View this email in your browser

MedNess: bite-size biopharma and medtech news

15th June, 2022
Subscribe here
MedNess This Week
HIGHLIGHTS
 
Drug Approvals
European Commission approves bispecific antibody Lunsumio for people with relapsed or refractory follicular lymphoma
“We are delighted that Lunsumio is the first bispecific antibody approved in Europe for people with relapsed or refractory follicular lymphoma,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “Lunsumio’s high response rates, off-the-shelf availability, and initial outpatient administration could transform how advanced follicular lymphoma is treated.”
European Commission approves Tecentriq as adjuvant treatment for patients with PD-L1 high resected Stage II-III NSCLC
“Today’s approval represents an important advance, as Tecentriq becomes the first cancer immunotherapy approved in Europe for the treatment of certain types of early-stage NSCLC,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “Since approximately half of all people with early NSCLC develop recurrence after surgery, which in some cases is no longer curable, treating this cancer at an earlier stage offers the best chance to prevent recurrence.”
Conference Coverage: Highlights from 27th Annual Meeting of the European Hematology Association (EHA2022)
  1. AbbVie Announces Late-Breaking Results from Ph 2 Trial of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Patients with R/R Large B-cell Lymphoma (LBCL)
  2. AbbVie Presents Investigational Navitoclax Preliminary Data in JAK Inhibitor Naïve Myelofibrosis Patients
  3. ADC Therapeutics Announces Results from Pivotal Ph 2 Clinical Trial of Camidanlumab Tesirine (Cami) in Relapsed or Refractory Hodgkin Lymphoma
  4. AstraZeneca Demonstrates Pipeline And Portfolio Strength Across Malignant And Rare Haematological Diseases
  5. CRISPR Therapeutics Presents Positive Results from its Phase 1 COBALT™-LYM Trial of CTX130™ in Relapsed or Refractory T Cell Malignancies
  6. Genmab Announces Late-Breaking Ph 2 Trial Results of Investigational Epcoritamab (DuoBody®-CD3xCD20) in R/R Large B-cell Lymphoma (LBCL) Patients
  7. Janssen Presents Updated Results Evaluating First-in-Class GPRC5D Bispecific Antibody Talquetamab in Heavily Pretreated Patients with Multiple Myeloma
  8. MEI Pharma and Kyowa Kirin Report Clinical Data on Zandelisib
  9. New Data Demonstrates AbbVie's VENCLYXTO®/VENCLEXTA® Combination Sustained PFS in CLL Patients After Four Years Off Treatment
  10. New IMBRUVICA (ibrutinib) Data in Fixed-Duration Combination Regimen Presented at Shows Deep, Durable Response at Three Years in 1L CLL
  11. Novartis five-year Kymriah® data show durable remission and long-term survival maintained in children and young adults with advanced B-cell ALL
  12. Oncternal Therapeutics Presents Rationale and Plans for its Registrational Ph 3 Study Evaluating Zilovertamab in Combination with Ibrutinib
  13. Roche announces positive data from broad blood cancer portfolio
MedNess Business
Onco-News
Umoja Biopharma and TreeFrog Therapeutics announce collaboration to address current challenges facing ex vivo allogeneic therapies in immuno-oncology
“Together, the successful pairing of Umoja’s RACR™ engineered iPS cells and TreeFrog’s C-Stem™ technology could overcome several challenges facing ex vivo allogeneic therapies,” said Ryan Larson, Ph.D., Vice President and Head of Translational Science at Umoja. “Two major industry-wide challenges include the ability to scale iPSC-based culture while maintaining cell health, quality, and efficient immune cell differentiation. TreeFrog’s biomimetic C-Stem™ technology is the perfect complementary development platform for our RACR™ technology, a pairing which could result in controlled, efficient iPSC expansion and differentiation into immune cells, with improved yields and quality. In addition to enhancing the differentiation and yield of immune cells within the manufacturing process, our RACR™ system should bring therapeutic benefit to patients, allowing for safe in vivo engraftment and persistence of tumor-killing cells without requirements for toxic lymphodepleting chemotherapy.”
Collated by: Richa Tewari, PhD 
Editors' Desk
Richa Tewari, PhD
Oncology News
Debarati Banik
HealthIT
Sohini Dutta
BioPharma News
MedNess Plus
Shalini Roy Choudhury
Genes and Therapy
Managing Editor
Nisha Peter, PhD
Consulting Editor
Share Share
Tweet Tweet
Forward Forward
Subscribe
Disclaimer
The editors take care to share authentic information.  In case of any discrepancies please write to medness.newsletter@gmail.com
The sponsors do not have any influence on the nature or kind of the news/analysis reported in MedNess. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of Medness. Examples of analysis performed within this article are only examples. They should not be utilized in real-world analytic products as they are based only on very limited and dated open source information. Assumptions made within the analysis are not reflective of the position of anyone volunteering or working for Medness. This blog is strictly for news and information. It does not provide medical advice, diagnosis or treatment nor investment suggestions. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
Copyright © 2019 MedNess , All rights reserved.
You are receiving this MedNess Newsletter as a subscriber on the list.

Cover Image : iStock
Images : Twitter , Unsplash.com
Content Editors: Richa Tewari , Esha Sehanobish , Rinki Saha ,  Shilpa Rawal, PhD ,  Debarati Banik  , Divyaanka Iyer , Arundithi Ananthanarayanan and Abhinav Dey 
Concept and Design: Ananda Ghosh and Nisha Peter
Our mailing address is:
MedNess
1150 First Ave. King of Prussia,, PA 19406

Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list.